Performance of KROS Keros Therapeutics Inc | 12.5% in 12m

Compare KROS with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?

Compare Keros Therapeutics Inc with its related Sector/Index XBI

Compare Keros Therapeutics Inc with its related Sector/Index XBI

Performance Duell KROS vs XBI

TimeFrame KROS XBI
1 Day 0.75% -0.03%
1 Week 1.98% -1.47%
1 Month 6.54% 8.61%
3 Months -17.0% 17.87%
6 Months -8.63% 12.16%
12 Months 12.5% 17.05%
YTD 12.2% 8.20%
Rel. Perf. 1m -0.19
Rel. Perf. 3m -2.98
Rel. Perf. 6m -2.40
Rel. Perf. 12m -2.40

Is Keros Therapeutics Inc a good stock to buy?

Neither. Based on ValueRay Analyses, Keros Therapeutics Inc is currently (July 2024) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 31.47 and therefor a technical neutral rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of KROS as of July 2024 is 43.18. This means that KROS is currently overvalued and has a potential downside of -10.75% (Sold with Premium).

Is KROS a buy, sell or hold?

  • Strong Buy: 9
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
Keros Therapeutics Inc has received a consensus analysts rating of 4.82. Therefor, it is recommend to buy KROS.
Values above 0%: KROS is performing better - Values below 0%: KROS is underperforming

Compare KROS with Broad Market Indices

Symbol 1w 1m 6m 12m
US S&P 500 SPY 3.94% 5.85% -23.15% -10.07%
US NASDAQ 100 QQQ 5.94% 7.68% -21.79% -14.70%
US Dow Jones Industrial 30 DIA 1.27% 3.49% -15.99% -3.41%
German DAX 40 DBXD 5.15% 6.05% -17.89% 2.79%
UK FTSE 100 ISFU 3.76% 5.52% -22.01% 2.44%
Shanghai Shenzhen CSI 300 CSI 300 0.31% 4.61% -16.10% 20.93%
Hongkong Hang Seng HSI 4.31% 7.94% -9.11% 28.23%
Japan Nikkei 225 EXX7 6.19% 4.64% -12.12% 4.00%
India NIFTY 50 INDA 3.54% 4.30% -21.92% -13.67%
Brasil Bovespa EWZ 5.93% 3.37% 3.61% 23.59%

KROS Keros Therapeutics Inc vs. Sectors

Symbol 1w 1m 6m 12m
Communication Services XLC 3.37% 5.42% -22.98% -18.43%
Consumer Discretionary XLY 3.90% 2.60% -16.48% 2.50%
Consumer Staples XLP 1.15% 5.16% -18.64% 6.59%
Energy XLE -0.06% 3.39% -25.71% 1.04%
Financial XLF 0.87% 2.85% -22.47% -9.95%
Health Care XLV 2.25% 5.14% -15.46% 1.95%
Industrial XLI 1.42% 4.86% -20.40% -3.07%
Materials XLB 2.41% 5.53% -19.13% 3.05%
Real Estate XLRE 0.68% -0.08% -15.09% 4.79%
Technology XLK 7.51% 9.84% -19.35% -13.66%
Utilities XLU 3.57% 5.26% -25.52% 6.26%
Aerospace & Defense XAR 2.01% 4.16% -19.78% -5.67%
Biotech XBI 3.45% -2.07% -20.79% -4.56%
Homebuilder XHB -1.26% -2.27% -26.13% -23.88%
Retail XRT 3.95% 6.30% -19.46% -2.90%

KROS Keros Therapeutics Inc vs. Commodities

Symbol 1w 1m 6m 12m
Oil USO 4.78% 8.32% -21.97% 2.15%
Natural Gas UNG 9.72% 31.40% 22.62% 63.11%
Gold GLD 2.60% 4.90% -26.62% -9.74%
Silver SLV 7.07% 11.22% -37.75% -7.04%
Copper CPER 8.79% 12.52% -20.45% 1.38%

Returns of KROS vs. Yields & Bonds

Symbol 1w 1m 6m 12m
iShares 20+ Years Bond TLT 3.07% 7.33% -9.36% 17.22%
iShares High Yield Corp. Bond HYG 1.98% 5.13% -12.86% 2.39%
Does Keros Therapeutics Inc outperform its market, is KROS a Sector Leader?
No, over the last 12 months Keros Therapeutics Inc (KROS) made 12.49%, while its related Sector, the SPDR S&P Biotech (XBI) made 17.05%.
Over the last 3 months KROS made -16.99%, while XBI made 17.87%.
Period KROS XBI S&P 500
1 Month 6.54% 8.61% 0.69%
3 Months -16.99% 17.87% 11.23%
12 Months 12.49% 17.05% 22.56%